Author: openjargon

Only a small group of ASX shares have the accolade of increasing their dividend every year for the past decade. This is because it can be challenging to grow the payout annually, as profit can dramatically change from year to year due to trading conditions or shifts in commodity prices.

Businesses operating in resilient industries are the ones that grow profit quite consistently. That’s important because it’s profit generation that funds dividend payments. The below ASX shares are among the leading stocks for regular dividend growth, though dividend hikes are not guaranteed.

Washington H. Soul Pattinson and Co. Ltd (ASX: SOL)

Soul Pattinson has the best record on the ASX when it comes to consecutive dividend increases. Its annual ordinary dividend has grown every year since 2000. The business has paid a dividend every year since 2000.

It has achieved this by owning a portfolio of assets that generate defensive or uncorrelated cash flows, such as telecommunications, resources, swimming schools, property and electrification.

TPG Telecom Ltd (ASX: TPG), Brickworks Limited (ASX: BKW), New Hope Corporation Ltd (ASX: NHC), Macquarie Group Ltd (ASX: MQG), Wesfarmers Ltd (ASX: WES) and BHP Group Ltd (ASX: BHP) are some of Soul Patts’ biggest ASX holdings.

The ASX share currently offers a grossed-up dividend yield of just over 4%.

APA Group (ASX: APA)

APA owns a large portfolio of gas pipelines around the country, transporting half of the country’s gas usage. It also owns gas storage, gas processing, gas-powered energy generation, electricity transmission assets, and renewable energy generation (solar and wind) assets.

The business has grown its payout yearly since 2004, so it has had two consecutive decades of growth.

APA’s cash flow pays for the distribution, which has steadily increased as the business completes more energy projects. A large majority (over 90%) of its revenue is linked to inflation and has seen elevated growth in the last couple of years.

The Australian federal government has confirmed that gas will continue to contribute to Australia’s energy mix for decades to come.

APA has guided it expects to pay a distribution per security of 56 cents in FY24, which is a forward distribution yield of 6.5%.

Sonic Healthcare Ltd (ASX: SHL)

Sonic is one of the world’s leading pathology businesses, with a presence in several countries including Australia, the US, Germany and the UK.

It has increased its dividend every year since 2013 and it has grown its dividend almost every year in the last three decades, with only a few years during that period when the dividend was maintained.

The ASX share has a stated “progressive dividend policy”, where the board aims to increase the payout for shareholders. The last two dividends amount to a dividend yield of 4.3%, excluding franking credits.

Inflation may be hurting Sonic’s short-term profitability, but the company is hopeful for the future, with its investments in artificial intelligence (AI) a key focus.

The post 3 ASX shares with a long history of increasing dividends appeared first on The Motley Fool Australia.

More reading

• If I had to own only one ASX 200 share forever, this would be it
• 2 of the best ASX 200 blue chip shares that money can buy
• These ASX dividend shares offer 6%+ yields right now
• Here are the top 10 ASX 200 shares today
• Why these 4 ASX 200 shares just got downgraded by top brokers

Motley Fool contributor Tristan Harrison has positions in Brickworks, Sonic Healthcare, and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Brickworks, Macquarie Group, Washington H. Soul Pattinson and Company Limited, and Wesfarmers. The Motley Fool Australia has positions in and has recommended Apa Group, Brickworks, Macquarie Group, Washington H. Soul Pattinson and Company Limited, and Wesfarmers. The Motley Fool Australia has recommended Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

There are a lot of ASX stocks to choose from on the Australian share market.

But not all are buys at current levels. In fact, some could even be sells. But which ones are buys and which ones are sells?

Let’s take a look at one ASX stock that could be a buy and one that could be a sell according to analysts at Goldman Sachs.

The ASX stock to buy

The first stock we’re going to look at is cloud accounting platform provider Xero Ltd (ASX: XRO).

It impressed the market last week when it released its FY 2024 results and delivered revenue and profit growth ahead of expectations.

The good news is that analysts at Goldman Sachs believe there’s still a significant growth runway ahead for Xero. It highlights that the company currently has a touch under 4.2 million subscribers from an addressable market of over 100 million. The broker commented:

We see Xero as very well-placed to take advantage of the digitisation of SMBs globally, driven by compelling efficiency benefits and regulatory tailwinds, with >100mn SMBs worldwide representing a >NZ$100bn TAM. Given the company’s pivot to profitable growth and corresponding faster earnings ramp, we see an attractive entry point into a global growth story with Xero our preferred large-cap technology name in ANZ – the stock is Buy rated.

Goldman has a conviction buy rating and $164.00 price target on its shares. This implies potential upside of 22% for investors from current levels.

The ASX stock to sell

An ASX stock to sell according to analysts at Goldman Sachs is Commonwealth Bank of Australia (ASX: CBA).

The broker believes that Australia’s largest bank’s shares are severely overvalued at current levels and could be destined to fall materially. It commented:

We are Sell-rated on CBA given: While CBA’s volume momentum in housing lending has improved and BDDs charges remain benign, we don’t think this justifies the extent of CBA’s valuation premium to peers. Coupled with i) a business mix that leaves it more exposed to the current competitive environment, and ii) while CBA has historically done a good job in balancing investment and productivity, we do not think it can escape elevated FY24E cost pressures given heightened inflation.

Goldman currently has a sell rating and $82.61 price target on the ASX stock. Based on its current share price of $120.10, this implies potential downside of 31% for investors over the next 12 months.

The post One ASX stock to buy and one to sell appeared first on The Motley Fool Australia.

More reading

• Are CBA share buyers getting the highest growth in return for being the most expensive?
• 2 no-brainer ASX 200 shares to buy next week
• Here’s how the ASX 200 market sectors stacked up last week
• Top brokers name 3 ASX shares to buy next week
• Hoping to retire? I’d buy these ASX 200 dividend shares for passive income

Motley Fool contributor James Mickleboro has positions in Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and Xero. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price was in fine form on Monday.

The ASX 200 pharma stock ended the day almost 16% higher at $23.97.

This means that Neuren Pharmaceuticals’ shares are now up 78% since this time last year.

It also means that they are now trading within sight of their record high of $25.95.

But if you thought the gains were over, think again. That’s because the team at Bell Potter believes that this ASX 200 stock can rocket to a new record high.

What is the broker saying about this ASX 200 stock?

Bell Potter was pleased with the top-line results from Neuren Pharmaceuticals’ phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS). Those results revealed that NNZ-2591  delivered a “statistically significant improvement” across all four efficacy measures.

The ASX 200 stock’s CEO, Jon Pilcher, commented: “We are very excited about the results of this first clinical trial in Pitt Hopkins patients. This underserved community has such urgent unmet need and we can now continue towards our goal of developing a first approved treatment.”

Commenting on the results, Bell Potter said:

Another favourable mean CGI-I score of 2.6, albeit from a small sample size of 11 subjects. Anything under 3.5 would’ve been positive (lower=better), hence clearly a good result in our view. We are again impressed to see nearly half (=5/11) of subjects achieving a CGI-I score of 1 or 2, meaning the clinical investigator deemed their symptoms were “very much” or “much” improved from baseline. These larger responses after 13 weeks’ treatment are less likely to be due to a placebo effect in our view. As a comparison, in the trofinetide Phase 3 trial, only 5% on placebo and 13% on trofinetide achieved a CGI-I score of 1 or 2, versus 45% in today’s data.

Big returns ahead

In response to the trial results, the broker has retained its buy rating with an improved price target of $28.00.

Based on the current Neuren Pharmaceuticals share price of $23.97, this implies potential upside of 17% for investors over the next 12 months. It would also mean a new record high for its shares.

The broker concludes:

Following today’s further clinical validation of NNZ-2591 we increase our PT by 6% to $28.00 and maintain our BUY recommendation. Roughly half of our PT is comprised of value ascribed to NNZ-2591, which has now shown encouraging clinical data in two indications, each of which represent a similar if not larger market opportunity than Rett syndrome. For both completed Phase 2 indications, no approved treatments are available and NNZ-2591 is comfortably in poll position to be the first drug to market. A third Phase 2 readout with NNZ-2591 in Angelman syndrome is expected in Q3 CY24.

The post This ASX 200 stock can rocket to a record high: Broker appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Tuesday
• Here are the top 10 ASX 200 shares today
• Why Cettire, Lendlease, Neuren, and Sayona Mining shares are racing higher today
• Guess which ASX 200 healthcare share just rocketed 11% on ‘groundbreaking trial’
• ASX 200 healthcare stock up 40% in 6 months halted ahead of major trial results

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

If you have a high tolerance for risk, then it could be worth thinking about adding the speculative ASX stock in this article to a balanced portfolio.

The stock in question is IperionX Ltd (ASX: IPX).

What is IperionX?

IperionX is aiming to become a leading American titanium metal and critical materials company.

It is using patented metal technologies to produce high performance titanium alloys from titanium minerals or scrap titanium. This is achieved with lower energy, low costs and low carbon emissions.

The company notes that its Titan critical minerals project is the largest JORC-compliant mineral resource of titanium, rare earth, and zircon minerals sands in the United States.

This leaves it well positioned to benefit from demand for titanium metal and critical minerals for advanced U.S. industries. This includes space, aerospace, defence, consumer electronics, hydrogen, electric vehicles, and additive manufacturing.

Why is this a speculative ASX stock to buy?

According to a note out of Bell Potter, its analysts think this ASX stock could be seriously undervalued at current levels.

The note reveals that the broker has reaffirmed its speculative buy rating with an improved price target of $3.85. Based on its current share price of $2.19, this implies potential upside of 76% for investors over the next 12 months.

To put that into context, a $10,000 investment would be worth approximately $17,600 by this time next year if Bell Potter is on the money with its recommendation.

Though, it is worth acknowledging that its speculative rating means that there’s potential for sizeable losses as well. That’s why this ASX stock is likely to be only suitable for investors that have a much higher than average risk tolerance.

What is the broker saying?

Bell Potter believes that the company has the potential to disrupt the titanium supply chain with its technology. It explains:

IPX has the potential to disrupt the incumbent titanium supply chain through materially lowering production costs and manufacturing waste. Large-scale production will commence this year, further de-risking the company’s technologies and enabling IPX to progress commercial relationships with several high-profile aerospace, automotive, luxury goods and government end users.

Our valuation is mostly supported by Phase 2 earnings using relatively conservative assumptions with respect to process margins. There is potential for IPX to rapidly scale Phase 2 and cement itself as a key supplier in the US and global titanium value chains. Our IPX valuation is now $3.85/sh (previously $3.70/sh), having removed the assumption of a near-term equity raise and its corresponding dilution.

All in all, the broker believes IperionX could have a very bright future ahead of it. This could make it one to watch very closely.

The post This disruptive speculative ASX stock could rise 75% in 12 months appeared first on The Motley Fool Australia.

More reading

• These 3 ASX All Ords stocks turned $500 into at least $16,500 in less than a decade!
• Why Fletcher Building, Healius, Iperionx, and Iress shares are sinking today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

I’ve already bought the two cheap ASX dividend shares in this article. They’re wonderful picks for passive income in retirement.

The higher interest rate environment is harming some sectors more than others. Within the pain, I think there are a few opportunities on the ASX.

And I’d much rather buy undervalued businesses than, say, the Commonwealth Bank of Australia (ASX: CBA), which, based on its earnings multiple and price-to-book ratio, is one of the most expensive banks in the world.

So, if I were investing in companies because of the dividend yield and value on offer, the below two would be among the names at the top of my buy list.

Metcash Ltd (ASX: MTS)

Metcash is a diversified business with three core segments.

It supplies independent supermarkets around Australia, namely IGAs. The company also supplies independent liquor retailers, including IGA Liquor, Bottle-O, Cellarbrations, and Porters Liquor. The food and liquor divisions can, in my opinion, provide stable earnings because of the largely consistent demand by households.

I’m excited about the company’s hardware division, which includes Total Tools, Mitre 10, and Home Timber & Hardware.

Hardware earnings are currently facing headwinds amid the high cost-of-living environment households and builders are in. I think Metcash can return to good earnings growth when economic conditions improve.

I like the company’s recent move to buy one of the country’s largest frame and truss businesses and a food service business that supplies other businesses, such as restaurants, cafes, hotels, hospitals, and others.

The ASX dividend share has committed to a dividend payout ratio of 70% of underlying net profit after tax (NPAT), which means it can pay a relatively high dividend yield. According to the estimates on Commsec, Metcash could pay a grossed-up dividend yield of 7.7% in FY24.

It looks cheap to me because it’s trading at just 13x FY24’s estimated earnings, whereas blue-chip peers like Wesfarmers Ltd (ASX: WES) and Coles Group Ltd (ASX: COL) are trading at higher earnings multiples.

Rural Funds Group (ASX: RFF)

Rural Funds is a cheap ASX dividend share, in my opinion, because the farmland real estate investment trust (REIT) is trading at a significant discount to its underlying net asset value (NAV).

According to Rural Funds (and independent property valuers), the business had an adjusted NAV of $3.07 at 31 December 2023. That means the current Rural Funds share price is at a discount of around 34% to the latest disclosed NAV.

The business is seeing its rental income steadily grow thanks to rental indexation built into most of its contracts. Some of those rental increases are linked to inflation, while other contracts have a fixed annual increase.

Rural Funds has grown or maintained its distribution every year for the past decade. In the longer term, it wants to grow its annual distribution by 4% per annum.

The business has good farmland diversification across cattle, almonds, macadamias, vineyards and cropping. Diversification is useful as a form of protection against risk, so not all the eggs are in one basket. Being open to investing in multiple farming sectors gives the business more opportunities.

Its trailing distribution yield is 5.8%, which I believe is a solid starting yield for this cheap ASX dividend share.

The post 2 cheap ASX dividend shares I’d buy in retirement appeared first on The Motley Fool Australia.

More reading

• Analysts say these 4 ASX dividend shares are buys
• Why I keep loading up on these 2 ASX passive income machines
• Top ASX stock to buy as a thrifty investor (the old Warren Buffett way)
• 4 ASX income stocks to buy for 4% to 8% dividend yields
• 2 cheap ASX dividend shares I’d buy for income

Motley Fool contributor Tristan Harrison has positions in Metcash and Rural Funds Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Wesfarmers. The Motley Fool Australia has positions in and has recommended Coles Group, Rural Funds Group, and Wesfarmers. The Motley Fool Australia has recommended Metcash. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The uranium sector has been a great place to invest over the last 12 months.

During this time, a number of ASX 200 uranium stocks have delivered stunning returns for their lucky shareholders.

However, one uranium stock that may have peaked now is Paladin Energy Ltd (ASX: PDN).

That’s the view of analysts at Bell Potter, which have just downgraded the uranium miner’s shares.

Why has this ASX 200 uranium stock been downgraded?

According to a note, the broker has downgraded its shares to a hold rating (from buy) with a trimmed price target of $15.70 (from $16.50). This is largely in line with the current Paladin Energy share price of $15.74.

Bell Potter recently visited the company’s Langer Heinrich Mine (LHM) in Namibia and was impressed with what it saw. In fact, it sees scope for Paladin Energy to surprise to the upside with its earnings. It said:

In summation, we were surprised at the quality of the site/ regional infrastructure and competency of the local workforce. The restart & ramp up appears to be running smoothly, which could provide upside risks to our earnings.

However, there are risks for investors to consider. One of these comes from its operating costs. It adds:

On the flip-side, we are cautious on operating costs which seem to be the biggest downside risk at this point. Based on the assumptions in the restart plan (2021) PDN anticipated a US$15.74/t milled ore mining cost. In our mind, there is no doubt that this figure has increased, however the Namibian Rand has depreciated 10% against the US$ since that period. Overall, we have factored in a 5% increase to US$ mining costs going forward.

In addition, Bell Potter highlights that there is an election coming up in Namibia, which could throw a spanner into the works. It explains:

In the upcoming election (Nov), key risks remain with the potential for an introduction of a Government free-carry interest and/or an increase in mining taxes being discussed. At this stage, the likelihood is unknown however the impact should these measures be introduced could be substantial.

Shares downgraded

In light of the above and with the ASX 200 uranium stock rallying hard over the last 12 months, the broker has decided to downgrade its shares to a hold rating. It summarised its decision:

Our target price for PDN decreases slightly to $15.70/sh (previously $16.50/sh) and we downgrade to a Hold. We walked away from the site tour with a positive outlook on LHM, however note that the stock has appreciated 140% over the past twelve months and at current levels looks fully valued, on our estimates. Further appreciation from here will be driven by 1) improving uranium pricing (PDN has ~80% market exposure through to 2030, our near-term price assumes a near-term price of US$115/lb vs spot of $92/lb), 2) expansion and exploration to the west of the current mining lease at LHM, and 3) potential M&A activity as LHM reaches a steady state of production.

The post Guess which ASX 200 uranium stock was just downgraded appeared first on The Motley Fool Australia.

More reading

• ASX 200 shares vs. property: Which has performed better since the COVID crash?
• Is the Paladin Energy share price overcooked at $17.40?
• Here are the top 10 ASX 200 shares today
• Will ASX uranium shares run higher on this ‘historic’ supply ban?
• Why Judo Capital, NAB, Paladin Energy, and Perpetual shares are falling today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

On Monday, the S&P/ASX 200 Index (ASX: XJO) started the week in a very positive fashion. The benchmark index rose 0.8% to 7,788.3 points.

Will the market be able to build on this on Tuesday? Here are five things to watch:

ASX 200 expected to rise

The Australian share market is expected to rise again on Tuesday. According to the latest SPI futures, the ASX 200 is poised to open the day 18 points or 0.25% higher. Wall Street was closed for the Memorial Day holiday and the UK market was closed for a bank holiday. However, the DAX and CAC were open for business and had positive sessions. Each rose 0.45% overnight.

Elders goes ex-dividend

The Elders Ltd (ASX: ELD) share price will be trading ex-dividend on Tuesday and could trade lower. Last week, the agribusiness company released its half year results and reported a sharp profit decline. This forced the Elders board to cut its interim dividend by 22% to 18 cents per share. The company’s shares will trade ex-dividend for this partially franked dividend this morning. After which, eligible shareholders can look forward to receiving it in their bank accounts next month on 26 June.

Oil prices rise

It could be a good session for ASX 200 energy shares including Santos Ltd (ASX: STO) and Karoon Energy Ltd (ASX: KAR) after oil prices pushed higher overnight. According to Bloomberg, the WTI crude oil price is up 1.1% to US$78.55 a barrel and the Brent crude oil price is up 1.1% to US$83.04 a barrel. Optimism over an upcoming OPEC+ meeting appears to have given prices a boost.

Neuren rated as a buy

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price can keep rising according to analysts at Bell Potter. Despite rising almost 16% on Monday, the broker believes there are still strong gains ahead for the ASX 200 pharma stock. Bell Potter responded to the company’s trial results by reiterating its buy rating and lifting its price target to $28.00. This implies potential upside of almost 17% for investors over the next 12 months.

Gold price rises

ASX 200 gold shares Evolution Mining Ltd (ASX: EVN) and Regis Resources Limited (ASX: RRL) could have a good session on Tuesday after the gold price rose overnight. According to CNBC, the spot gold price is up 0.8% to US$2,352.5 an ounce. Traders were buying the precious metal ahead of the release of US inflation data this week.

The post 5 things to watch on the ASX 200 on Tuesday appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• Why Cettire, Lendlease, Neuren, and Sayona Mining shares are racing higher today
• Guess which ASX 200 healthcare share just rocketed 11% on ‘groundbreaking trial’
• 5 things to watch on the ASX 200 on Monday
• Here’s how the ASX 200 market sectors stacked up last week

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Elders. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

You might have heard someone talk about the recent Powerball jackpot at your most recent barbeque or water cooler gathering. Nothing gets as a-gossiping more it seems than a monstrous, life-changing jackpot up for grabs. Certainly not ASX shares.

Last week’s $150 million Powerball jackpot remains unclaimed at the time of writing, although we do know that the winning ticket was purchased in South Australia.

Whilst this gargantuan amount of cash has understandably got everyone talking (and dreaming), it’s probably worth discussing the pitiful odds of this windfall coming to you.

According to reporting from the ABC, mathematician Adam Spencer has estimated that the odds of winning last week’s $150 million jackpot was a staggering 134 million to one. Here’s how that looks written out:

134,000,000,000 : 1

Spencer expanded by walking us through the maths:

First of all, you have to get seven correct out of 35… That is a one in 6.8 million chance. If you get through that hoop, you then have a one in 20 chance of getting the final ball. The total odds are one in 134 million.

Not much of a gambler myself, I like the idea of getting a decent return on one’s cash using ASX shares instead.

Buying an ASX share almost certainly isn’t going to make you a millionaire 134 times over in one day. However, the probability of you building life-changing wealth using the share market is a lot more appealing than buying a lottery ticket.

So if you missed out on last week’s jackpot, here are two ASX shares I think you’d be better off buying than another long-shot lotto ticket.

Two ASX shares I’d buy over a lottery ticket

First up is the Vanguard Australian Shares Index ETF (ASX: VAS). This index fund isn’t really an individual ASX share, but represents an investment in a whole bunch.

How many? Well, VAS tracks the S&P/ASX 300 Index (ASX: XKO), which means it holds the largest 300 shares on the Australian share market within it.

That’s everything from Commonwealth Bank of Australia (ASX: CBA) and Woolworths Group Ltd (ASX: WOW) to Telstra Group Ltd (ASX: TLS) and Harvey Norman Holdings Limited (ASX: HVN).

Think of this index fund as buying a small share of all the lottery tickets on the ASX. You won’t get rich overnight. But over time, you’ll enjoy the average return of the entire stock market.

This average return has historically been rewarding. Since this index fund’s inception in 2009, it has averaged a return of 8.97% per annum (as of 30 April).

Whilst past performance is never a guarantee of future returns, I think an index fund like VAS is about as good as it gets if you’re looking for a sturdy long-term investment.

If you can’t win the Powerball, buy it

Next, we have Lottery Corp Ltd (ASX: TLC). Yep, none other than the very ASX share that runs the Powerball.

Lottery Corp has exclusive licenses to run lotteries and Keno in most Australian states and territories. Whilst only one person tends to benefit from a Powerball win, every single Lottery Corp shareholder benefits when a Powerball ticket is sold.

As such, I think you’d be better off betting on the ASX share that runs the Powerball than trying to beat those one in 134 million odds.

Lottery comparisons aside, I like Lottery Corp as an ASX share investment. We all tend to want to try our luck with a lotto ticket or at Keno in all kinds of economic weather. That makes Lottery Corp a reliable and defensive investment in my view.

Additionally, this company pays a decent, fully franked dividend, which means that there’s a good chance (a lot better than the lotto) you’ll get paid every six months just for owning this company’s shares.

The post Forget lottery tickets, I’d buy these ASX shares instead appeared first on The Motley Fool Australia.

More reading

• $1,000,000 portfolio: One way to achieve 7-figure wealth
• Here’s what $10,000 invested in the Vanguard Australian Shares Index ETF (VAS) at the start of 2023 is worth now
• Could buying the Vanguard Australian Shares Index ETF (VAS) at under $100 help me retire early?
• Here’s how the ASX 200 market sectors stacked up last week
• How I plan to invest my tax cuts

Motley Fool contributor Sebastian Bowen has positions in Telstra Group and Vanguard Australian Shares Index ETF. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Lottery. The Motley Fool Australia has positions in and has recommended Harvey Norman and Telstra Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.